Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Specifically, at the highest dose tested (12 mg weekly), nausea occurred in roughly 45 to 60 percent of participants
A key differentiator of Mardrigals resmetirom is that in a pivotal Phase 3 trial, it achieved both primary endpoints of NASH resolution and reduction in fibrosis (MAESTRO-NASH), the two liver histological improvement endpoints the FDA has proposed as reasonably likely to predict clinical benefit
& Eriksson, J
doi: 10.1111/dom.15802
Regular check-ups can monitor health changes, ensuring the treatment stays on track with your goals
US$ 24.85
US$ 26.87
US$ 28.26
